A startup called Vero, which was spun out of some foundational proteomics research at Stanford University, is hoping to beta test a proteomics product for consumers this year.
“Knowing your oldest organ isn’t the point; changing the trajectory is,” Vero co-founder and CEO Paul Coletta told a crowd gathered at the Near Future Summit in Malibu, California, last month.
The company plans to make its test available to consumers for around $200 a pop, at scale. Their draw only requires one vial of blood.